Dermatologic Events Associated with the Anti-CCR4 Antibody Mogamulizumab: Characterization and Management

The CCR4-directed monoclonal antibody mogamulizumab has been shown to significantly improve progression-free survival and overall response rate compared with vorinostat in adults with relapsed/refractory mycosis fungoides (MF) and Sézary syndrome (SS). One of the most common adverse events seen with...

Descripción completa

Detalles Bibliográficos
Autores principales: Musiek, Amy C. M., Rieger, Kerri E., Bagot, Martine, Choi, Jennifer N., Fisher, David C., Guitart, Joan, Haun, Paul L., Horwitz, Steven M., Huen, Auris Onn-Lay, Kwong, Bernice Y., Lacouture, Mario E., Noor, Sarah J., Rook, Alain H., Seminario-Vidal, Lucia, Vermeer, Maarten H., Kim, Youn H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8776934/
https://www.ncbi.nlm.nih.gov/pubmed/34816383
http://dx.doi.org/10.1007/s13555-021-00624-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8776934/
https://www.ncbi.nlm.nih.gov/pubmed/34816383
http://dx.doi.org/10.1007/s13555-021-00624-7

Ejemplares similares